L'intérêt à découvert pour Elevance Health donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Elevance Health. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Elevance Health (NYSE:ELV) Stock, Rapport sur les intérêts à découvert

Elevance Health

Elevance Health remains one of the leading health insurers in the US, providing medical benefits to 46 million medical members as of December 2024. The company offers employer, individual, and government-sponsored coverage plans. Elevance differs from its peers in its unique position as the largest single provider of Blue Cross Blue Shield branded coverage, operating as the licensee for the Blue Cross Blue Shield Association in 14 states. Through acquisitions, such as the Amerigroup deal in 2012 and MMM in 2021, Elevance's reach expands beyond those states through government-sponsored programs, such as Medicaid and Medicare Advantage plans, too. It is also an emerging player in pharmacy benefit management and other healthcare services.

Elevance Health Inc

Electrovaya Inc

Evolva Holding SA

Evolva Holding SA ADR

ELVICTOR GROUP INC by Elvictor Group, Inc

Elvictor Group Inc

Enliven Therapeutics, Inc. - Common Stock

Enliven Therapeutics Inc

ELEVATE URANIUM LTD by Elevate Uranium Ltd.

Elevate Uranium Ltd

EVOLVA HLDG AG S/ADR by Evolva Holding AG

WIIM

IONQ

IonQ shares are trading higher after the company announced it has entered into an agreement with Toyota Tsusho to advance quantum computing in Japan.

Boeing Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BA#NASDAQ">BA</a>) and Exxon Mobil Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>) just got their own rollercoasters &#8211; and no, we're not talking about production delays <a href="https://www.benzinga.com/topic/oil">or crude prices.</a> 
This week, traders woke up to four new ways to ride the headlines: the launch of single-stock daily leveraged and inverse ETFs for Boeing and Exxon Mobil by Direxion.
<h2 class="wp-block-heading">Why Traders Might Love (Or Loathe) BOEU And XOMX</h2>
The tickers? Say hello to the Direxion Daily BA Bull 2X Shares&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOEU#NASDAQ">BOEU</a>)&nbsp;and the Direxion Daily BA Bear 1X Shares&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOED#NASDAQ">BOED</a>) for Boeing bulls and bears respectively, and the Direxion Daily XOM Bull 2X Shares&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XOMX#NASDAQ">XOMX</a>)&nbsp;and the Direxion Daily XOM Bear 1X Shares&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XOMZ#NASDAQ">XOMZ</a>), for those looking to double down or short swing with Exxon.
These aren't your average buy-and-hold ETFs. They're more like caffeinated trading tools for the fast-fingered crowd &#8211; built to capitalize on daily movements in two of the market's most headline-prone names. 
Boeing has its hands full with FAA oversight and airline orders, while Exxon's fate is often one crude tweet &#8211; or crude barrel &#8211; away from volatility.
"These two are magnets for market-moving news," said Direxion's CEO Douglas Yones. Whether it's jet orders from Asia or OPEC surprises, both names offer a steady stream of catalysts for day traders, he said.
Read Also: <a href="https://www.benzinga.com/economics/macro-economic-events/25/04/44886429/oils-not-dead-yet-smart-money-thinks-the-bottoms-in">Oil&#8217;s Not Dead Yet &#8211; Smart Money Thinks The Bottom&#8217;s In</a>
<h2 class="wp-block-heading">The Risky Ride Of Single-Stock ETFs</h2>
But before anyone gets too excited, these ETFs aren't for the faint of heart. Leveraged and inverse single-stock ETFs are explicitly short-term tools. With no diversification and high daily reset risks, they're the financial equivalent of riding a fighter jet through a thunderstorm.
So while BOEU and XOMX may not make headlines like Trump Media &amp; Technology Group Corp or GameStop Corp, they're poised to carve out their own niche among traders looking to cash in on daily noise. 
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44941804/boeing-gears-up-for-q1-print-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-analysts">Boeing Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street&#8217;s Most Accurate Analysts</a></li>
</ul>
Photo: Ground Picture/Shutterstock.com

Long Ideas

Specialty ETFs

New ETFs

Tech

Trading Ideas

ETFs

BOED

BOEU

XOMX

XOMZ

From Oil Rigs To Runways: Exxon Mobil, Boeing Get The Leveraged Trading Treatment

News

Nextera Energy Currently Estimates Energy Resources Has Less Than $150M In Tariff Exposure Through 2028; Says Tariff Exposure On Batteries Is Expected To Be Negligible

M/I Homes shares are trading higher. The company reported Q1 financial results.

ATI shares are trading higher after Keybanc upgraded the stock from Sector Weight to Overweight and announced a price target of $55. Additionally, the company announced it has ratified a new six-year labor agreement with the United Steelworkers.

First Community (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCCO#NASDAQ">FCCO</a>) reported quarterly earnings of $0.51 per share which beat the analyst consensus estimate of $0.45 by 13.33 percent. This is a 50 percent increase over earnings of $0.34 per share from the same period last year. The company reported quarterly sales of $18.37 million which beat the analyst consensus estimate of $17.39 million by 5.64 percent. This is a 20.39 percent increase over sales of $15.26 million the same period last year.

Earnings

Earnings Beats

FCCO

First Community Q1 EPS $0.51 Beats $0.45 Estimate, Sales $18.37M Beat $17.39M Estimate

Tempus AI shares are trading higher after the company announced a multi-year collaboration with several firms, including AstraZeneca, to develop the largest multimodal foundation model in oncology.

Otis Worldwide Corporation&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OTIS#NYSE">OTIS</a>) shares are trading lower premarket on Wednesday after the company after the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/n44944440/otis-reports-first-quarter-2025-results" rel="noreferrer noopener">company reported first-quarter&nbsp;results</a>.
The company reported: 
<ul>
<li>A sales decline of 3% year over year (Y/Y) to $3.35 billion, missing the analyst&#8217;s estimate of $3.37 billion due to New Equipment in China. </li>
<li>Organic sales remained flat Y/Y.</li>
<li>Net sales in the New Equipment segment fell 9% year over year to $1.16 billion, mainly due to an over 20% decline in China and a high-single-digit decrease in the Americas.</li>
<li>Meanwhile, Service segment net sales rose 1%&nbsp;Y/Y to&nbsp;$2.19 billion. Organic maintenance and repair sales increased&nbsp;3%&nbsp;Y/Y and organic modernization sales upped&nbsp;10% Y/Y.</li>
<li>Adjusted operating profit decreased 1% Y/Y to&nbsp;$560 million, with adjusted operating profit margin expanding 40 basis points to&nbsp;16.7%, led by favorable Service segment performance and mix.</li>
<li>Adjusted EPS of 92 cents, up&nbsp;5% Y/Y, beat the&nbsp;<a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">analysts' estimates of 91 cents</a>.</li>
<li>In the&nbsp;quarter, operating cash flow stood at&nbsp;$190 million, and adjusted free cash flow came in at&nbsp;$186 million.</li>
<li>Repurchased shares of $250 million in the quarter.</li>
</ul>
2025&nbsp;Outlook: The company raised net sales guidance to $14.6 billion-$14.8 billion (from $14.1&nbsp;billion&nbsp;to&nbsp;$14.4 billion)&nbsp;vs. consensus of&nbsp;$14.53 billion, with organic sales&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">growth of&nbsp;2%&nbsp;to&nbsp;4%</a>.
The company reaffirmed guidance for an adjusted operating profit of $2.4 billion-$2.5 billion, adjusted EPS of&nbsp;$4.00-$4.10&nbsp;(vs. consensus of&nbsp;$4.06), and adjusted free cash flow of around&nbsp;$1.6 billion.
Adjusted operating profit guidance excludes tariff impact: losses of $75 million to $45 million. Including the tariff impact, the projected increase at constant currency would be $105 to $135 million.
CEO Judy Marks said, &#8220;We continued to execute our modernization strategy with orders up 12% leading to a mid-teens backlog growth that sets us up well for the rest of the year. We also grew our industry leading maintenance portfolio 4% again this quarter,&#8221;
Dividend: On Tuesday, Otis declared a quarterly dividend increase of 8% to 42 cents per share, payable on June 6, 2025, to shareholders of record as of May 16, 2025.
Investors can gain exposure to the stock via&nbsp;AdvisorShares Focused Equity ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CWS#NYSE">CWS</a>) and&nbsp;Brookstone Value Stock ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/BAMV#BATS">BAMV</a>).
Price Action:&nbsp;OTIS shares are down&nbsp;2.98%&nbsp;at&nbsp;$96.00&nbsp;premarket at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/04/44933914/atkore-expects-strong-solid-q2-performance-despite-flags-impairment-charge-reaffirms-fy25-outlook" target="_blank" rel="noreferrer noopener">Atkore Expects Strong Solid Q2 Performance Despite Flags Impairment Charge, Reaffirms FY25 Outlook</a></li>
</ul>
Image: Shutterstock

Asia

Equities

Large Cap

Guidance

Movers

BAMV

OTIS

Otis Raises Sales Forecast As China Drag Weighs On Elevator Giant

John Marshall Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JMSB#NASDAQ">JMSB</a>) reported quarterly earnings of $0.34 per share. This is a 13.33 percent increase over earnings of $0.30 per share from the same period last year.

JMSB

John Marshall Bancorp Q1 EPS $0.34 Up From $0.30 YoY

BOOT

Boot Barn Holdings shares are trading higher. Baird maintained an Outperform rating on the stock.

Goldman Sachs is eyeing a high-reward opportunity in copper that could pay off big if the U.S. follows through on i<a href="https://www.benzinga.com/topic/donald-trump">ts protectionist policy shift.</a>
In a note published on Wednesday, Goldman Sachs analysts led by Eoin Dinsmore outlined a bullish view on what they are calling "The Copper Tariff Trade," a strategy built on the expectation of a potential import tax from the Trump Administration.
<h3 class="wp-block-heading">What's Happening With Copper Tariffs?</h3>
In February, the Trump Administration launched a formal investigation into copper imports under Section 232 — a process used to determine if certain imports pose a national security risk. It's the same move that led to tariffs on steel and aluminum years ago.
&#8220;For metals there is a stated and very real commitment to tariffs, which we believe they will deliver on,&#8221; Dinsmore wrote.
Goldman Sachs thinks copper is next in line. The bank says there's a 90% chance the U.S. will impose a 25% import tariff on foreign copper, possibly as soon as June. But right now, markets are acting like there's only a 60% chance of that happening.
That's where the trade opportunity comes in.
<h3 class="wp-block-heading">The Trade: Bet On COMEX Over LME Copper</h3>
Goldman says the market is underpricing this risk and suggests a tactical move: go long the December 2025 COMEX–London Metal Exchange copper arbitrage.
The trade Goldman likes is based on the price difference between copper traded in the U.S. – on COMEX – and globally, on the London Metal Exchange.
In simpler terms, bet that U.S. copper prices will jump relative to global ones if tariffs are put in place. Right now, U.S. copper for December delivery is trading $1,707 per metric ton higher than global prices — an 18% premium.
If a 25% tariff becomes reality, Goldman says that spread should widen to $2,287 per ton.
The United States Copper Index Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPER#NYSE">CPER</a>) is the only U.S.-listed ETF that invests in COMEX copper futures, offering investors direct exposure to U.S. copper prices tied to domestic market dynamics.
<h3 class="wp-block-heading">How Fast Could Copper Tariffs Happen?</h3>
Goldman's base case assigns a 55% probability that the tariff will be announced by the end of June—just 125 days after the investigation began. 
This expectation is supported by a March 26 press report suggesting tariffs could arrive "within weeks." Another scenario, with a 30% probability, pushes the decision to August or early September, based on a 180-day timeline used in previous investigations of critical minerals.
Regardless of the exact timing, the final decision must be made by December 2025, which is why Goldman favors the December COMEX-LME arbitrage trade.
<h3 class="wp-block-heading">How High Could Tariff Rate On Copper Go?</h3>
Goldman's model suggests a "fair" probability-weighted tariff of 22.5% on U.S. copper imports. That figure comes from assigning a 90% probability to a full 25% tariff and 10% to a no-tariff scenario. 
Notably, the investment bank indicated that a middle-ground 10% tariff is "hard to rationalize," especially since copper was excluded from the baseline 10% tariffs already in effect.
<h3 class="wp-block-heading">Why Copper? National Security, Economic Policy, China's Dominance</h3>
The U.S. imports nearly 50% of the refined copper it uses — about 725,000 metric tons last year, worth around $7 billion. That's up from just 25% back in 2010.
Domestic copper production has dropped by 20% since 2010 due to high costs and tough regulations, while global production — mostly in China — has increased by 40%. So even as U.S. demand rises, more copper is coming from abroad, especially from countries like Chile, Peru and Canada.
&#8220;The Trump Administration believes the US&#8217; reliance on copper imports leaves consuming sectors vulnerable to supply disruptions,&#8221; Goldman Sachs stated.
This worries policymakers. Copper is used in defense systems, power grids, electric vehicles, and even AI technology — all areas closely tied to national and economic security.
<h3 class="wp-block-heading">Could Tariffs Boost US Copper Output?</h3>
Goldman expects tariffs to encourage more investment in copper recycling and might help restart idle smelters and refineries. It could also reduce demand for copper exports by making them pricier overseas.
The bigger shift could come from Washington's push to fast-track mining permits. If that goes through, U.S. copper mine production could get a real lift, yet not until the early 2030s.
Photo: Shutterstock

Macro Economic Events

Econ #s

Economics

CPER

Goldman Sachs Backs 'Copper Tariff Trade' If Trump Slaps 25% Duty On US Imports

Grand Cayman, Cayman Islands, April 23, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLXN#NASDAQ">SLXN</a>) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced a strategic collaboration with Catalent, a global leader in advanced delivery technologies, clinical development, and manufacturing solutions for therapeutics.
Under the agreement, Catalent will conduct formulation development and clinical manufacturing activities for Silexion's next-generation siRNA candidate, SIL204, at its state-of-the-art facility in Limoges, France. The collaboration will focus on optimizing both the systemic and intratumoral delivery formulations of SIL204, supporting Silexion's recently announced dual-route development strategy designed to target both primary tumors and metastases in KRAS-driven cancers.
This collaboration builds upon Silexion's recently reported breakthrough preclinical data demonstrating SIL204's significant efficacy in reducing both primary tumor growth and metastatic spread in clinically relevant orthotopic pancreatic cancer models. SIL204 targets a broad spectrum of KRAS mutations (including G12D, G12V, G12R, Q61H, and G13D), which are critical drivers in pancreatic, colorectal, and lung cancers.
This collaboration is part of Silexion's comprehensive strategy to advance SIL204 through preclinical development and into clinical trials, with plans to conduct additional toxicology and pharmacodynamic studies throughout 2025, followed by potential regulatory submissions to the Israel Ministry of Health in the second half of 2025 and to the European Union in the first half of 2026.
 &nbsp;

SLXN

Silexion Therapeutics Collaborates With Catalent On Advanced siRNA Formulation Development & Clinical Manufacturing Activities

DDOG

Datadog shares are trading higher after the company announced it has acquired Metaplane, a data observability platform.

CPNG

Coupang shares are trading higher after the company announced a partnership with the Department of Commerce's International Trade Administration to aid American businesses in selling overseas.

Evercore ISI Group analyst John Pancari maintains Synchrony Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYF#NYSE">SYF</a>) with a Outperform and lowers the price target from $64 to $56.

Price Target

Analyst Ratings

Evercore ISI Group Maintains Outperform on Synchrony Financial, Lowers Price Target to $56

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Compass Point analyst Dominick Gabriele initiated coverage on PayPal Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPL#NASDAQ">PYPL</a>) with a Sell rating and announced a price target of $56. PayPal shares closed at $61.42 on Tuesday. <a href="https://www.benzinga.com/quote/PYPL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>HC Wainwright &amp; Co. analyst Sameer Joshi initiated coverage on Oklo Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKLO#NYSE">OKLO</a>) with a Buy rating and announced a price target of $55. Oklo shares closed at $21.53 on Tuesday. <a href="https://www.benzinga.com/quote/OKLO/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>UBS analyst Peter Grom initiated coverage on General Mills, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GIS#NYSE">GIS</a>) with a Sell rating and announced a price target of $54. General Mills shares closed at $58.06 on Tuesday. <a href="https://www.benzinga.com/quote/GIS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Roth MKM analyst Taz Koujalgi initiated coverage on SentinelOne, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/S#NYSE">S</a>) with a Buy rating and announced a price target of $26. SentinelOne shares closed at $16.36 on Tuesday. <a href="https://www.benzinga.com/quote/S/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JMP Securities analyst Silvan Tuerkcan initiated coverage on Foghorn Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FHTX#NASDAQ">FHTX</a>) with a Market Outperform rating and announced a price target of $9. Foghorn Therapeutics shares closed at $4.24 on Tuesday.  <a href="https://www.benzinga.com/quote/FHTX/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying PYPL stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="578" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/23091816/image-136-1024x578.png" alt="" class="wp-image-884194" style="width:551px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/23091816/image-136-1024x578.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/23091816/image-136-300x169.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/23091816/image-136-768x434.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/23091816/image-136.png 1103w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44920101/top-2-tech-and-telecom-stocks-you-may-want-to-dump-this-quarter">Top 2 Tech And Telecom Stocks You May Want To Dump This Quarter</a> </li>
</ul>
Photo via Shutterstock

Initiation

Pre-Market Outlook

Markets

FHTX

OKLO

PYPL

This PayPal Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Wednesday

Pentair shares are trading higher. Barclays raised its price target on the stock from $110 to $111 and maintained an Overweight rating, while Baird maintained an Outperform rating.

A new Reuters/Ipsos poll suggests a decrease in approval for President Donald Trump&#8216;s management of the U.S. economy and inflation&nbsp;as he approaches his 100th&nbsp;day in office.
What Happened: Trump&#8217;s assertive economic strategies, including trade wars and Federal Reserve pressure, have triggered the most severe U.S. financial markets selloff since the early stages of the COVID pandemic. The poll, which ended on Monday, showed that only 37% of participants approve of Trump&#8217;s economic management, a decrease from 42% after his January 20 inauguration, reported Reuters.
James Pethokoukis, a senior fellow&nbsp;at the&nbsp;American Enterprise Institute, referred to the president&#8217;s unmet promise of a &#8220;Golden Age of America&#8221;. He hinted that the economic red flags might compel Trump to reconsider his tariff policies.
The survey also disclosed that 75% of participants fear an upcoming recession. Fifty-six percent of those surveyed—including 25% of Republicans—described Trump's economic decisions as &#8220;too erratic,&#8221; while two-thirds expressed concern over the recent sharp decline in the stock market.
A majority (52%) believe Trump&#8217;s actions could hurt their retirement comfort, compared to 31% who disagreed. Still, his overall approval rating holds at 42%, higher than Biden's for much of his term.
SEE ALSO:&nbsp;<a href="https://benzinga.com/25/04/44919745/tesla-shifts-cybertruck-marketing-strategy-to-appeal-to-traditional-pick-up-truck-customers-amid-poor-sales" target="_blank" rel="noreferrer noopener">Cybertruck Gets A Down-To-Earth Redesign As Tesla Shifts To Traditional Pickup Marketing Amid Poor Sales</a>
Why It Matters: This decline in approval for Trump&#8217;s economic policies comes after a&nbsp;<a href="https://www.benzinga.com/news/25/04/44890428/trumps-gallup-approval-stands-at-45-topping-same-point-in-first-presidency-but-hes-down-16-in-economist-survey">Gallup poll</a>&nbsp;in April showed Trump&#8217;s approval rating at 45%, despite economic uncertainty. This was a slight improvement from his 41% approval rating one quarter into his first term. However, an Economist/YouGov poll showed a 16-point drop since his January inauguration.
Earlier in March, an <a href="https://www.benzinga.com/news/global/25/03/44183107/trumps-approval-rating-48-voters-disapprove-of-handling-of-russia-ukraine-war-55-think-world-war-to-happen">Emerson College poll</a> revealed Trump&#8217;s approval rating remained steady at 49%, even as his handling of the Russia-Ukraine war divided voters. The recent Reuters/Ipsos poll results indicate a continuing downward trend in approval for Trump&#8217;s economic policies, reflecting growing public concern over the economy and financial markets.
Price Action: Invesco QQQ Trust, Series 1 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) dropped 9.4%, while SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) declined more than 8% over the past month. 
<ul>
<li>READ MORE:&nbsp;<a href="https://benzinga.com/markets/25/04/44944439/warren-buffett-i-am-100-for-the-independence-of-the-fedand-for-over-20-years-hes-warned-we-do-not-want-to-fool-around-with-it" target="_blank" rel="noreferrer noopener">Warren Buffett Said &#8216;I Am 100% For The Independence Of The Fed:&#8217; For Over 20 Years, He&#8217;s Warned, &#8220;We Do Not Want To Fool Around With It&#8221; &#8211; Benzinga</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Trump Economic Approval Rating Drops To 37% As Market Selloff Erodes Public Support: Poll

Evercore ISI Group analyst Stephen Kim maintains PulteGroup (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHM#NYSE">PHM</a>) with a Outperform and raises the price target from $161 to $165.

Evercore ISI Group Maintains Outperform on PulteGroup, Raises Price Target to $165

Taiwan-based&nbsp;United Microelectronics Corp&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UMC#NYSE">UMC</a>) reported <a target="_blank" href="https://www.benzinga.com/topic/semiconductors" rel="noreferrer noopener">fiscal first-quarter</a> results Wednesday.
The company reported <a href="https://www.umc.com/en/Download/quarterly_results/QuarterlyResultsDetail/2025/2025Q1" target="_blank" rel="noreferrer noopener">quarterly revenue growth</a> of 5.9% year-on-year to $1.74 billion (NT$57.86 billion). It also missed the analyst consensus estimate of $1.81 billion. 
Here&#8217;s a breakdown of the release:
Also Read: <a href="https://www.benzinga.com/25/04/44587473/globalfoundries-explores-merger-with-umc-to-strengthen-us-semiconductor-industry" target="_blank" rel="noreferrer noopener">GlobalFoundries Explores Merger With Taiwan&#8217;s UMC To Strengthen US Semiconductor Industry</a>
<ul>
<li>The revenue decreased by 4.2% Q/Q.</li>
<li>Earnings per ADS of 9 cents missed the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">analyst consensus estimate </a>of 10 cents. The stock price gained after the report.</li>
<li>Revenue from 22 and 28nm was 37% of the wafer revenue (versus 33% a year ago), driven by a 46% Q/Q increase in 22nm revenue from products such as OLED display driver ICs, image signal processors as well as digital TV, WiFi, and audio codec chips.</li>
<li>The 40nm contribution remained at 16% of&nbsp;sales (versus 18% a year ago).&nbsp;</li>
<li>Capacity utilization improved from 65% to 69% Y/Y.</li>
<li>The gross margin declined to 26.7% from 30.9% a year ago. Capital expenditures totaled $443 million in the quarter.</li>
</ul>
Outlook: United Microelectronics <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">expects second-quarter</a> wafer shipments to increase by 5-7% and ASP to remain flat. It expects quarterly gross margin of ~30%. The company projected capacity utilization in the mid-70% range for the quarter.
The company reiterated <a target="_blank" href="https://www.benzinga.com/25/01/43095433/umc-q4-earnings-topline-rises-99-driven-by-ai-and-smartphones-projects-flat-q1-shipments" rel="noreferrer noopener">2025 capex of </a>$1.8 billion.
Co-president Jason Wang projected a moderate rebound in demand across all segments in the second quarter. Beyond that, he expressed caution about wafer demand projections as policies and markets are still adjusting to the recent tariff announcements. United Microelectronics focused on execution of key technology projects, such as the 12nm collaboration with U.S. partner, and ensuring our customers have access to geographically diverse manufacturing options. It also implemented cost-reduction plans and accelerated AI and intelligent manufacturing systems.
The company expects customers to tape out additional 22nm products in the coming quarters. The newly inaugurated Singapore Phase 3 fab will provide a further 22nm capacity to support future growth. Pilot runs are underway, and the company is scheduled to ramp up to volume production in early 2026.
Price Action:&nbsp;UMC stock is up 5.88% at $7.20 premarket at the last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44932684/coreweaves-first-mover-advantage-and-gpu-expertise-drive-strong-growth-analysts-say" target="_blank" rel="noreferrer noopener">CoreWeave Garners Praise Due To AI Growth, Nvidia Partnership</a></li>
</ul>
Image: Shutterstock

United Microelectronics Boasts Q1 Gains, Faces Caution Over Tariff Impact On Future Orders

Legal

Press Releases

Elevance Health, Inc. Shareholders are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Elevance Health, Inc. Shareholders are Encouraged to Reach Out to Johnson Fistel for More Information about Potentially Recovering Their Losses

AM Best Affirms Credit Ratings of Elevance Health, Inc. and Its Subsidiaries

Robbins LLP Informs Elevance Health Inc. Stockholders that it is Investigating the Officers and Directors of ELV to Determine if They Breached Fiduciary Duties Owed to Shareholders

Elevance Health to Hold Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2024 Results on January 23, 2025

Mark Farrah Associates Delves into Acquisition Impacts Utilizing New Tools

Elevance Health Reports Fourth Quarter and Full Year 2024 Results; Sets Full Year 2025 Outlook

Elevance Health to Hold Conference Call and Webcast to Discuss First Quarter 2025 Results on April 22, 2025

Comments

Elevance Health

Intérêt court

Elevance Health (NYSE:ELV) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL